A thematic analysis of the strengths and weaknesses of manufacturers’ submissions to the NICE Single Technology Assessment (STA) process

Christopher Carroll, Eva Kaltenthaler, Patrick FitzGerald, Angela Boland and Rumona Dickson

Health Policy, 2011, vol. 102, issue 2, 136-144

Abstract: The NICE Single Technology Appraisal (STA) process in the UK has been underway for five years. Evidence Review Groups (ERGs) critically appraise submissions from manufacturers on the clinical and cost effectiveness of new technologies. This study analysed the ERGs’ assessment of the strengths and weaknesses of 30 manufacturers’ submissions to the STA process.

Keywords: Review; Systematic; Cost effectiveness; Cost benefit analysis; Pharmaceutical industry; Drug approval (search for similar items in EconPapers)
Date: 2011
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851011001126
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:102:y:2011:i:2:p:136-144

DOI: 10.1016/j.healthpol.2011.06.002

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().